Trovagene (TROV) Misses Q2 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Supermicro probe finds no senior management link to export violations
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
Cantor Fitzgerald Upgrades TrovaGene (TROV) to Buy
August 8, 2016 7:28 AM EDTCantor Fitzgerald upgraded TrovaGene (NASDAQ: TROV) from Hold to Buy with a price target of $7.00 (from $5.00).
For an analyst ratings summary and ratings history on TrovaGene click here. For more ratings news on TrovaGene click here.
Shares of TrovaGene closed at $5.20 yesterday.
... MorePiper Jaffray Remains Sidelined on Trovagene (TROV) Following 2Q Miss
August 5, 2016 10:04 AM EDTPiper Jaffray maintained a Neutral rating on TrovaGene (NASDAQ: TROV), and cut the price target to $4.00 (from $5.00), following the company's 2Q earnings report. Trovagene reported revenue of $104K, below the Street' ~$270K. Total revenue consisted of royalty revenue of $48K as well as test revenue of $56K.
Analyst William... More
